Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial Meeting Abstract
| Authors: | Konstantinopoulos, P.; Kim, J. W.; Freyer, G.; Lee, J. Y.; Gaba, L.; Grisham, R.; Colombo, N.; Wu, X.; Sehouli, J.; Cruz, F.; Cibula, D.; Monk, B.; Nyvang, G. B.; Friedlander, M.; Lorusso, D.; Van Nieuwenhuysen, E.; Glasspool, R.; Marth, C.; Hinson, P.; Zuradellit, M.; Wangt, C.; Su, F. Y.; Miller, M.; Matulonis, U.; González-Martín, A. |
| Abstract Title: | Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial |
| Meeting Title: | Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer |
| Journal Title: | Gynecologic Oncology |
| Volume: | 190 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Mar 15-18 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-11-01 |
| Start Page: | S12 |
| Language: | English |
| ACCESSION: | WOS:001330731400015 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.ygyno.2024.07.024 |
| Notes: | Meeting Abstract: 09 -- Source: Wos |
